CTMX - サイトメックス・セラピュ―ティクス (CytomX Therapeutics Inc.) サイトメックス・セラピュ―ティクス

 CTMXのチャート


 CTMXの企業情報

symbol CTMx
会社名 CytomX Therapeutics Inc (サイトメックス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 シートムエックス・セラピューティクス(CytomX Therapeutics Inc.)は臨床段階の腫瘍学に従事するバイオ医薬品会社である。同社はProbodyテクノロジープラットフォームを使用して、臨床的に検証された標的に対する癌免疫療法を創出して薬物標的に対する癌治療法を開発する。パイプラインはプロボディーガン免疫療法、プロボディー薬物コンジュゲート、T細胞関与プロボディー二重特異性、ProCAR-NK細胞療法の各種治療法の開発に焦点を当てる。同社の製品候補はCX-072、CX-2009、CX-2029、細胞傷害性Tリンパ球関連タンパク質4(CTLA-4)、CX-188等がある。Probodyプラットフォームは、モノクローナル抗体に基づく治療を可能にするために、腫瘍組織中の活性プロテアーゼを利用する。研究的Probody治療はCX-072指向のプログラム・デスリガンド1等の免疫腫瘍学における臨床的有効な癌標的に対処する。   サイトメックス・セラピュ―ティクスは米国のバイオ医薬品企業。主に「Probody」技術プラットフォ―ムに基づく抗体治療に焦点を当て、がん免疫治療の研究開発に従事する。同技術は、がん細胞の特殊な環境において抗体の働きを強め、同時に健康な細胞内では抗がん剤作用を押さえることを目標にする。「PD-L1」抗体薬の臨床試験を行う。本社はサンフランシスコ。   CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, based on its Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
本社所在地 151 Oyster Point Boulevard Suite 400 South San Francisco CA 94080 USA
代表者氏名 Hoyoung Huh 湖寧
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-515-3185
設立年月日 40422
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数
url www.cytomx.com
nasdaq_url https://www.nasdaq.com/symbol/ctmx
adr_tso
EBITDA EBITDA(百万ドル) -39.47600
終値(lastsale) 16.47
時価総額(marketcap) 740552007.24
時価総額 時価総額(百万ドル) 754.94040
売上高 売上高(百万ドル) 86.73900
企業価値(EV) 企業価値(EV)(百万ドル) 419.79440
当期純利益 当期純利益(百万ドル) -64.26600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CytomX Therapeutics Inc revenues increased 74% to $35.5M. Net loss decreased 14% to $28.9M. Revenues reflect Revenues increase of 83% to $35.5M. Lower net loss reflects Interest income increase from $442K to $2.9M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.91 to -$0.75.

 CTMXのテクニカル分析


 CTMXのニュース

   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs  2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.
   The Daily Biotech Pulse: ScPharma''s Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues  2021/07/14 11:48:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical Holding Company Ltd. . (NYSE: BHVN ) AngioDynamics, Inc. (NASDAQ: ANGO ) (reacted to its fiscal-year 2021 fourth-quarter results) Bicycle Therapeutics plc (NASDAQ: BCYC ) ( announced Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) exercised option to use its tissue-targeted delivery of oligonucleotide therapeutics tech) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Forward Pharma A/S (NASDAQ: FWP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) PLx Pharma Inc. (NASDAQ: PLXP ) (announced availability of FDA-approved liquid-filled aspirin capsules in Walmart Inc. (NYSE: WMT ) stores) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) Unicycive Therapeutics, Inc. (NASDAQ: UNCY ) (IPOed Tuesday) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 13) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc.
   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
   CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research  2021/06/21 12:00:00 Intrado Digital Media
CX-2029 is the first CD71-targeting antibody-drug conjugate (ADC) administrated to patients, with a generally well-tolerated safety profile at doses that elicit anti-tumor responses CX-2029 is the first CD71-targeting antibody-drug conjugate (ADC) administrated to patients, with a generally well-tolerated safety profile at doses that elicit anti-tumor responses
   Organovo, Iterum Therapeutics leads healthcare gainers; Provention Bio, Eton Pharmaceuticals among major losers  2021/05/28 15:03:32 Seeking Alpha
   Iterum keeps rising even as RBC analyst cautions, Premier hurt by Barclays’ double downgrade; and more in today’s analyst action  2021/05/28 12:59:51 Seeking Alpha
   FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes  2021/05/28 10:36:06 Seeking Alpha
   CytomX Therapeutics Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/02/23 20:11:00 Stock Market Daily
CytomX Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock  2021/01/20 21:50:00 Benzinga
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage, oncology-focused biopharmaceutical …
   Edited Transcript of CTMX earnings conference call or presentation 6-Aug-20 9:30pm GMT  2020/08/07 21:29:46 Yahoo Finance
Q2 2020 CytomX Therapeutics Inc Earnings Call
   Shareholder Alert: Robbins LLP Reminds Investors CytomX Therapeutics, Inc. (CTMX) Sued for Misleading Shareholders  2020/07/01 22:32:00 Business Wire
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $CTMX #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of CytomX Therapeutics, Inc. (NASDAQ: CTMX) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between May 17, 2018 and May 13, 2020. CytomX is an oncology-focused biopharmaceutical company in the United States. CytomX's lead product candidates in the clinical stage include CX-072 and CX-2009. If you suffered a loss
   Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CytomX Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – CTMX  2020/06/03 21:04:01 MarketScreener
NEW YORK, June 03, 2020 -- Pomerantz LLP announces that a class action lawsuit has been filed against CytomX Therapeutics Inc. and certain of its officers. The class action,…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サイトメックス・セラピュ―ティクス CTMX CytomX Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)